NCT00893607View on ClinicalTrials.gov

Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

December 31, 2007

Conditions
Fecal Incontinence
Interventions
DRUG

NRL001

10mg NRL001 was administered as a slow release suppository

Trial Locations (1)

NG7 2UH

Division of GI Surgery, University Hospital - Queens Medical Centre, Nottingham

Sponsors

Lead Sponsor

Norgine
All Listed Sponsors
lead

Norgine

INDUSTRY

NCT00893607 - Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum | Biotech Hunter | Biotech Hunter